CONFORMED
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) June 18, 1997
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822
25-1229323
(State of other jurisdiction (Commission File
Number) (IRS Employer
of incorporation)
Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
On June 18, 1997, Biocontrol Technology, Inc.
(NASDAQ:BICO) announced that preliminary data from the in-home
testing on the Diasensorr1000 noninvasive glucose sensor for
diabetics has been submitted to the Food and Drug Administration
(FDA). The in-home testing was required by the FDA and is part
of the overall approval process necessary to market the sensor.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information
and Exhibits.
(a) Financial Statements and Businesses Acquired - Not
Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits-Press Release
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: June 18, 1997
BICO
BIOCONTROL TECHNOLOGY, INC
2275 Swallow Hill Road, Building 2500
Pittsburgh, PA 15220
Press Release
Release: Immediate
For More Information, Call:
Investors Media
Diane McQuaide
Susan Taylor
1.412.429.0673 phone
1.412.279.9455 phone
1.412.279.9690 fax
1.412.279.9447 fax
BIOCONTROL SUBMITS PRELIMINARY DATA TO THE FDA
Pittsburgh, PA - June 18, 1997 - Biocontrol Technology, Inc.
(Nasdaq:BICO) announced today that preliminary data from the in-
home testing on the Diasensorr1000 noninvasive glucose sensor for
diabetics has been submitted to the Food and Drug Administration
(FDA). The in-home testing was required by the FDA and is part
of the overall approval process necessary to market the sensor.
Fred E. Cooper, chief executive officer, stated, "Although
we are still compiling the overall information, we have sent some
data from the in-home tests to the FDA for feedback. As we have
previously said, the calibration of patients in their own homes
rather than in calibration centers produced better results, and
we wanted to get some of this data into the hands of the FDA for
discussion prior to final summarization."
Biocontrol Technology, Inc. has its corporate offices in
Pittsburgh, PA and is involved in the development and manufacture
of biomedical devices and environmental products.
